These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 17934808

  • 21. Estrogen inhibits cell proliferation through in situ production in human thymoma.
    Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Nakata T, Sunamori M, Handa M, Kondo T, Sasano H.
    Clin Cancer Res; 2005 Sep 15; 11(18):6495-504. PubMed ID: 16166425
    [Abstract] [Full Text] [Related]

  • 22. Progestins and breast cancer.
    Pasqualini JR.
    Gynecol Endocrinol; 2007 Oct 15; 23 Suppl 1():32-41. PubMed ID: 17943537
    [Abstract] [Full Text] [Related]

  • 23. Breast cancer and steroid metabolizing enzymes: the role of progestogens.
    Pasqualini JR.
    Maturitas; 2009 Dec 15; 65 Suppl 1():S17-21. PubMed ID: 19962254
    [Abstract] [Full Text] [Related]

  • 24. Aromatase and the breast: regulation and clinical aspects.
    Miller WR.
    Maturitas; 2006 Jul 20; 54(4):335-41. PubMed ID: 16730141
    [Abstract] [Full Text] [Related]

  • 25. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
    Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB, Sasano H.
    Endocr Relat Cancer; 2008 Mar 20; 15(1):113-24. PubMed ID: 18310280
    [Abstract] [Full Text] [Related]

  • 26. Aromatase inhibitors and other novel agents in breast cancer treatment.
    Saji S, Toi M.
    Expert Opin Emerg Drugs; 2002 Oct 20; 7(2):303-19. PubMed ID: 15989553
    [Abstract] [Full Text] [Related]

  • 27. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
    Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T, Saeki T.
    J Steroid Biochem Mol Biol; 2003 Sep 20; 86(3-5):455-60. PubMed ID: 14623544
    [Abstract] [Full Text] [Related]

  • 28. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy.
    Day JM, Purohit A, Tutill HJ, Foster PA, Woo LW, Potter BV, Reed MJ.
    Ann N Y Acad Sci; 2009 Feb 20; 1155():80-7. PubMed ID: 19250195
    [Abstract] [Full Text] [Related]

  • 29. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
    Licznerska BE, Wegman PP, Nordenskjöld B, Wingren S.
    Breast Cancer Res Treat; 2008 Nov 20; 112(1):15-23. PubMed ID: 18030614
    [Abstract] [Full Text] [Related]

  • 30. [Steroid sulfatase inhibitor].
    Nakata T, Ishida H, Shiotsu Y.
    Nihon Rinsho; 2010 Jun 20; 68(6):1073-8. PubMed ID: 20535958
    [Abstract] [Full Text] [Related]

  • 31. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.
    Xu B, Kitawaki J, Koshiba H, Ishihara H, Kiyomizu M, Teramoto M, Kitaoka Y, Honjo H.
    Maturitas; 2007 Feb 20; 56(2):142-52. PubMed ID: 16962266
    [Abstract] [Full Text] [Related]

  • 32. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
    Brooks JD, Thompson LU.
    J Steroid Biochem Mol Biol; 2005 Apr 20; 94(5):461-7. PubMed ID: 15876411
    [Abstract] [Full Text] [Related]

  • 33. Aromatase inhibitors in breast cancer.
    Hiscox S, Davies EL, Barrett-Lee P.
    Maturitas; 2009 Aug 20; 63(4):275-9. PubMed ID: 19577386
    [Abstract] [Full Text] [Related]

  • 34. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.
    Foster PA, Newman SP, Chander SK, Stengel C, Jhalli R, Woo LL, Potter BV, Reed MJ, Purohit A.
    Clin Cancer Res; 2006 Sep 15; 12(18):5543-9. PubMed ID: 17000691
    [Abstract] [Full Text] [Related]

  • 35. Intratumoral estrogen production in breast carcinoma: significance of aromatase.
    Suzuki T, Miki Y, Ohuchi N, Sasano H.
    Breast Cancer; 2008 Sep 15; 15(4):270-7. PubMed ID: 18622573
    [Abstract] [Full Text] [Related]

  • 36. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
    Day JM, Tutill HJ, Purohit A, Reed MJ.
    Endocr Relat Cancer; 2008 Sep 15; 15(3):665-92. PubMed ID: 18541621
    [Abstract] [Full Text] [Related]

  • 37. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years.
    Honma N, Takubo K, Sawabe M, Arai T, Akiyama F, Sakamoto G, Utsumi T, Yoshimura N, Harada N.
    J Clin Endocrinol Metab; 2006 Feb 15; 91(2):607-13. PubMed ID: 16303840
    [Abstract] [Full Text] [Related]

  • 38. Steroid sulphatase inhibitors for breast cancer therapy.
    Purohit A, Woo LW, Chander SK, Newman SP, Ireson C, Ho Y, Grasso A, Leese MP, Potter BV, Reed MJ.
    J Steroid Biochem Mol Biol; 2003 Sep 15; 86(3-5):423-32. PubMed ID: 14623540
    [Abstract] [Full Text] [Related]

  • 39. Oestrogen formation in breast: clinical and biological importance.
    Dowsett M, Detre S, Rowlands M, Grimshaw R.
    J Endocrinol; 1996 Sep 15; 150 Suppl():S59-63. PubMed ID: 8943788
    [Abstract] [Full Text] [Related]

  • 40. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
    Aka JA, Mazumdar M, Lin SX.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):183-90. PubMed ID: 19038308
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.